Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Abstract : Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01934672
Contributor : Mouniati Colo <>
Submitted on : Monday, November 26, 2018 - 10:32:56 AM
Last modification on : Thursday, February 21, 2019 - 10:34:12 AM

Links full text

Identifiers

Collections

Citation

P Cottu, V d'Hondt, S Dureau, F Lerebours, I Desmoulins, et al.. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Annals of Oncology, Oxford University Press (OUP), 2018, ⟨10.1093/annonc/mdy448⟩. ⟨hal-01934672⟩

Share

Metrics

Record views

26